Search clinical trials for: i.v. recombinant human C1 inhibitor

Total 3760 results

Pharming Technologies B.V.

Completed

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Genetic Disorders

Netherlands
Pharming Technologies B.V.

Completed

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Genetic Disorders

Netherlands
Shire
Halozyme Therapeutics

Completed

A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase

Hereditary Angioedema

United States
Shire

Completed

Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks

Hereditary Angioedema (HAE)

United States, Germany, Spain, Sweden
Pharming Technologies B.V.

Completed

A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration (OPERA)

Hereditary Angioedema | Genetic Disorders

Netherlands, Romania
Shire

Completed

A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE

Hereditary Angioedema

United States
Shire

Completed

Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects

Hereditary Angioedema (HAE)

United States
AO GENERIUM

Withdrawn

Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema

Hereditary Angioedema

Russian Federation
Pharming Technologies B.V.

Completed

A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor

Hereditary Angioedema

United States, Canada, Czechia, Italy, Macedonia, The Former Yugoslav Republic of, Romania, Serbia
University Hospital, Basel, Switzerland
Pharming Technologies B.V.; Clinical Trial Unit, University Hospital Basel,...

Completed

Recombinant Human C1 Esterase Inhibitor in the Prevention of Contrast-induced Nephropathy in High-risk Subjects (PROTECT)

Acute Kidney Injury

Switzerland
Pharming Technologies B.V.

Completed

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Hereditary Angioedema | Angioneurotic Edema

Netherlands
Pharming Technologies B.V.

Completed

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Hereditary Angioedema | Genetic Disorders | Angioneurotic Edema

Netherlands, Romania
IMMUNOe Research Centers

Completed

A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions

CVI - Common Variable Immunodeficiency

United States
Shire

Completed

A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection

Graft Rejection

United States, Germany
Shandong University
Shandong Provincial Hospital; The First Affiliated Hospital of Dalian Medical...

Completed

An Investigation of rhTPO With Different Frequencies in the Management of ITP

Immune Thrombocytopenia

China
Shire

Completed

CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12

Hereditary Angioedema (HAE)

United States, Germany, Hungary
Pharming Technologies B.V.
University of Wisconsin, Madison

Withdrawn

Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation

Kidney Transplantation | Graft Rejection

United States
Shire

Completed

Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks (CHANGE 3)

Hereditary Angioedema

United States
Leiden University Medical Center
Takeda; Netherlands Brain Foundation

Recruiting

Complement Inhibition: Attacking the Overshooting Inflammation @Fter Traumatic Brain Injury (CIAO@TBI)

Traumatic Brain Injury | Trauma, Head

Netherlands
Peking Union Medical College
Shenyang Sunshine Pharmaceutical Co., LTD.

Unknown

Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP

Thrombocytopenia | Immune Thrombocytopenia | Idiopathic Thrombocytopenic Purpura

China
Shire

Completed

Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks (CHANGE 2)

Hereditary Angioedema

United States
Shire

Completed

Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects

Hereditary Angioedema

United States
Shire

Completed

C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks

Hereditary Angioedema

United States
Shire

Completed

Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

Hereditary Angioedema (HAE)

Spain, Israel, United States, Hungary, Germany, Canada, Romania
Massachusetts General Hospital

Completed

Recombinant Human Prolactin for Lactation Induction

Lactation

United States
Shire

Completed

C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks

Hereditary Angioedema

United States
Tianjin Medical University General Hospital

Unknown

Efficacy and Safety of Thrombopoietin In Patients With Severe and Very Severe Aplastic Anemia

Anemia, Aplastic

China
Steen Bonnema

Completed

rhTSH, Radioiodine Uptake and Goiter Reduction Following 131I Therapy in Patients With Benign Nontoxic Nodular Goiter

Nodular Goiter

Denmark
Merck KGaA, Darmstadt, Germany

Completed

r-hLIF for Improving Embryo Implantation in IVF

Infertility Implantation Failure
Merck KGaA, Darmstadt, Germany

Completed

A Multicentre, Randomised, Double-blind, Placebo-controlled Proof of Concept Study to Compare the Efficacy and Safety of r-hLIF (Emfilermin) for Improving Embryo Implantation Following in Vitro Fertilization (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure

Infertility Implantation Failure
Massachusetts General Hospital

Withdrawn

Recombinant Human Prolactin for Lactation Induction

Lactation

United States
Hongnan Mo

Unknown

Recombinant Human Thrombopoietin for Mobilization of Peripheral Blood Progenitor Cells for Autologous Transplantation

Hematopoietic Stem Cell Transplantation | Thrombocytopoietin | Hematopoietic Stem Cell Mobilization

China
Massachusetts General Hospital

Completed

The Safety and Efficacy of Recombinant Human Prolactin

Healthy

United States
Massachusetts General Hospital

Completed

Recombinant Human Prolactin for Lactation Induction

Lactation

United States
University of Milan
Eli Lilly and Company

Unknown

Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)

Growth Hormone Deficiency, Dwarfism | Pseudohypoparathyroidism

Italy
CSL Behring
Parexel

Completed

A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route

Hereditary Angioedema Types I and II

United States, Germany
Protgen Ltd

Completed

Phase II/III of Recombinant Human Serum Albumin

Hepatic Ascites

China
Protgen Ltd

Completed

Recombinant Human Serum Albumin in Healthy Subjects

Hepatic Ascites

China
BioMarin Pharmaceutical

Completed

An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease

Batten Disease | CLN2 Disease | Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 | Jansky-Bielschowsky Disease | CLN2 Disorder

United States, Germany, Italy, United Kingdom
Shandong University
The First Affiliated Hospital of Anhui Medical University; The Affiliated Hospital... and other collaborators

Completed

rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP

Purpura | Idiopathic Thrombocytopenic Purpura

China
The First Hospital of Jilin University

Completed

Phase Ib of Recombinant Human Albumin Injection

Ascites

China
Nanfang Hospital of Southern Medical University
First Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial People... and other collaborators

Unknown

Efficacy and Safety of rHuTPO on Platelet Engraftment After Allo-HSCT (TPO)

Allogeneic Hematopoietic Stem Cell Transplantation | Myeloablative | Delayed Platelet Engraftment

China
Shenyang Sunshine Pharmaceutical Co., LTD.

Unknown

The Tolerability，Safety，PK/PD Study of rhTPO in the Patients With Liver Function Impairment

Liver Cirrhosis

China
Institute of Hematology & Blood Diseases Hospital

Completed

Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients

Thrombocytopenia

China
Halozyme Therapeutics
Baxter Healthcare Corporation

Completed

Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex) (INFUSE-NSLR)

Healthy

United States
Chinese Society of Lung Cancer

Terminated

Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy

Carcinoma, Non-Small-Cell Lung

China
ZymoGenetics

Completed

Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer

Melanoma | Kidney Neoplasms | Metastases

United States
National Cancer Institute (NCI)

Completed

Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis

Psoriasis

United States
Chugai Pharmaceutical

Completed

A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

Chemotherapy Induced Anemia
Halozyme Therapeutics
Baxter Healthcare Corporation

Completed

Subcutaneous Rehydration Compared to Intravenous Rehydration (PEDs-II)

Dehydration

United States

Search clinical trials for: i.v. recombinant human C1 inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations